Connect Biopharma reports positive Phase 2 asthma, COPD data for rademikibart
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
2 stories
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
Luly plans to step down as president and CEO by February 1, 2027 after 23 years leading the company; Kieffer takes on a newly created operating role.
SEC filing